Antivirals

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

Retrieved on: 
Thursday, October 22, 2020
Research, Infectious diseases, Hospitals, FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Antivirals, Health, Articles, Organic compounds, Remdesivir, Gilead Sciences, Coronavirus disease, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GS-441524, the ACTT-1 Trial, the SIMPLE Trials

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization.
  • As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19.
  • Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury.
  • Based on the strength of these data, Veklury has become a standard of care for the treatment of COVID-19 in hospitalized patients.

Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19

Retrieved on: 
Tuesday, October 20, 2020
Medical specialties, Immunology, Medicine, Clinical medicine, Immune system, Biotechnology, Glycoproteins, Antivirals, Antibody, Monoclonal antibody, Neutralizing antibody

ABP 300 wasdeveloped to confer design features that potentially allow for more potent viral neutralization and higher safety benefits due to reduced antibody dependent enhancement (ADE), apotentialadverse side effect of monoclonal antibody therapies.

Key Points: 
  • ABP 300 wasdeveloped to confer design features that potentially allow for more potent viral neutralization and higher safety benefits due to reduced antibody dependent enhancement (ADE), apotentialadverse side effect of monoclonal antibody therapies.
  • ABP 300 is being co-developed withMabwell, a biotechnology company based in Shanghai, where Abpros Phase 1 trial is being conducted.
  • ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19thatwascreated using the latest technologies available for antibody discovery.
  • The Companys mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies.

Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19

Retrieved on: 
Monday, October 19, 2020
Zoonoses, Sarbecovirus, Animal diseases, Antivirals, COVID-19, Single-domain antibody, Coronavirus disease, Coronavir, Severe acute respiratory syndrome coronavirus, Infectious diseases, Medical specialties

NEW YORK and SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (Beroni or the Company), an Australia-based diversified biopharmaceutical enterprise, today announces successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548) (GenScript), a leading global biotechnology company.

Key Points: 
  • NEW YORK and SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (Beroni or the Company), an Australia-based diversified biopharmaceutical enterprise, today announces successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548) (GenScript), a leading global biotechnology company.
  • On September 7, 2020, Beroni and Genscript performed an experiment to identify the most effective nanobodies.
  • Beroni aims at developing coronavirus-specific nanobodies as a treatment of COVID-19, which can be targeted on lung by aerosolization, rather than by intravenous drug administration.
  • The samples potency on neutralization were evaluated by performing SARS-CoV-2 pseudovirus neutralization assay.

Cocrystal Pharma Provides Update on Influenza A Program

Retrieved on: 
Monday, October 19, 2020
Chemistry, Organic compounds, Medical specialties, Antivirals, RTT, Zoonoses, Prodrugs, Cocrystal, Crystallography, Orthomyxoviridae, Influenza, Baloxavir marboxil

BOTHELL, WA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), (Cocrystal or the Company), announces promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344, that is currently being evaluated in IND-enabling studies for the treatment of both seasonal and pandemic influenza strain A.

Key Points: 
  • BOTHELL, WA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), (Cocrystal or the Company), announces promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344, that is currently being evaluated in IND-enabling studies for the treatment of both seasonal and pandemic influenza strain A.
  • Cocrystals recent data shows that CC-42344 retained single digit nanomolar potency (EC50 = 0.5 nM) against Xofluza (baloxavir) resistant influenza A strain (H1N1, I38T).
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus.
  • Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

Retrieved on: 
Monday, October 19, 2020
Other Health, Research, Pharmaceutical, Infectious diseases, Genetics, Clinical trials, Science, Biotechnology, Stem cells, Medical Supplies, Other Science, Health, Cytokines, Antivirals, Synairgen, Interferon, Akron Biotechnology, Synairgen

Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgens wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients.

Key Points: 
  • Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgens wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients.
  • Akron Biotech provides cGMP-compliant solutions to support the development and commercialization of advanced therapies.
  • Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgens formulation.
  • The agreement with Synairgen reflects our ongoing commitment to meet the growing demand for validated, cGMP-compliant solutions to advance novel therapies, said Claudia Zylberberg, PhD, Founder and CEO of Akron Biotech.

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting

Retrieved on: 
Thursday, October 15, 2020
Medical specialties, Branches of biology, Immune system, Clinical medicine, Cytokines, Antivirals, Immunology, Lymphocytes, Natural killer cell, Interferon gamma, Interferon, Cytokine

4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.

Key Points: 
  • 4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.
  • IL-15 is a cytokine that bridges innate and adaptive immunity by promoting NK and T cell proliferation and NK cell cytotoxicity.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius Therapeutics manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News.

Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatment

Retrieved on: 
Wednesday, October 14, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Research, Science, Biotechnology, Antivirals, Medicine, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome coronavirus, Virology, Health, COVID-19 drug development, Lactiga, Mount Sinai Health System

Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients.

Key Points: 
  • Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients.
  • We are proud to partner with Mount Sinai, which has maintained a leading role in COVID-19 research and innovation.
  • To date, preliminary in vitro studies demonstrate full neutralization of SARS-CoV-2 viral components, emphasizing the potential applicability of LCTG-001 to COVID-19 infections.
  • Lactiga has engaged the United States Food and Drug Administration through the Coronavirus Treatment Acceleration Program to optimize its transition from research toward first-in-human clinical testing.

America’s Top Young Scientist of 2020: 14-Year-Old Researches Spike Protein of SARS-CoV-2 Virus to Develop Novel Antiviral Drug to Combat Spread of COVID-19

Retrieved on: 
Wednesday, October 14, 2020
Research, Teens, Infectious diseases, General Health, Consumer, Health, Primary, Secondary, Science, Education, Other Science, Health, Medical specialties, Medicine, Animal virology, Antivirals, Peplomer, Virology, Coronavirus, Virus, Severe acute respiratory syndrome coronavirus, Coronavir, Antibody-dependent enhancement

View the full release here: https://www.businesswire.com/news/home/20201014005340/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201014005340/en/
    Anika Chebrolu named America's Top Young Scientist at this years 3M Young Scientist Challenge (Photo: 3M).
  • With the virus continuing to spread far and wide, there is an urgent need to find an effective anti-coronavirus drug.
  • In her study, Anika discovered a molecule that can selectively bind to the spike protein of the SARS-CoV-2.
  • Binding and inhibiting this viral protein would potentially stop the virus entry into the cell, creating a viable drug target.

Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model

Retrieved on: 
Wednesday, October 14, 2020
Antiviral drug, Biocides, Antivirals, Biology

To evaluate the ability of its NITRICIL platform technology as a potential nasal treatment option for COVID-19, the Company initiated in vitro assessments targeting the reduction of viral burden in differentiated normal human bronchial epithelial cells.

Key Points: 
  • To evaluate the ability of its NITRICIL platform technology as a potential nasal treatment option for COVID-19, the Company initiated in vitro assessments targeting the reduction of viral burden in differentiated normal human bronchial epithelial cells.
  • The studies were conducted at the Institute for Antiviral Research at Utah State University and these results demonstrate the first instance of an antiviral effect from a nitric oxide-based medicine in a 3-D tissue model that has similar structure to the human airway epithelium.
  • The results from the in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated that berdazimer sodium reduced 90% of virus after repeat dosing, once daily.
  • COVID-19 continues to have a major ongoing impact on global health and there remains a direct need for a safe and effective antiviral therapy.

ION Manufacturing Unveils ZnTech: A Revolutionary Zinc Fiber Microcurrent That Kills Coronavirus

Retrieved on: 
Friday, October 9, 2020
Manufacturing, Infectious diseases, Hospitals, Health, Textiles, Medicine, Clinical medicine, Health, Antivirals, Biocides, Antiviral drug, Oxygen, Respiratory therapy, Virus, Coronavir, Oxygen therapy

ION Manufacturing is among the first U.S.-based companies to come to market with scientifically-verified zinc-based antiviral technology.

Key Points: 
  • ION Manufacturing is among the first U.S.-based companies to come to market with scientifically-verified zinc-based antiviral technology.
  • ZnTech fully destroys viral pathogens, while most currently available antiviral technology employs chemicals that only retard or repel viral particles.
  • Market competitors often employ coatings of other metals, such as Copper and Silver, neither of which are capable of generating the microcurrent essential to kill Coronavirus.
  • This ground-breaking zinc fiber matrix interacts with exhaled moisture and oxygen, or oxygen from the skins surface, to generate the microcurrent.